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Background: Longitudinal data assessing the impact of iodine deficiency (ID) on mortality are scarce. We
aimed to study the association between the state of iodine nutrition and the risk of total and cause-specific
mortality in a representative sample of the Spanish adult population.
Methods: We performed a longitudinal observational study to estimate mortality risk according to urinary iodine
(UI) concentrations using a sample of 4370 subjects >18 years representative of the Spanish adult population
participating in the nationwide study Di@bet.es (2008–2010). We used Cox regression to assess the association
between UI at the start of the study (<50, 50–99, 100–199, 200–299, and ‡300 lg/L) and mortality during follow-
up (National death registry—end of follow-up December 2016) in raw models, and adjusted for possible con-
founding variables: age, sex, educational level, hypertension, diabetes, obesity, chronic kidney disease, smoking,
hypercholesterolemia, thyroid dysfunction, diagnosis of cardiovascular disease or cancer, area of residence,
physical activity, adherence to Mediterranean diet, dairy and iodinated salt intake.
Results: A total of 254 deaths were recorded during an average follow-up period of 7.3 years. The causes of death were
cardiovascular 71 (28%); cancer 85 (33.5%); and other causes 98 (38.5%). Compared with the reference category with
adequate iodine nutrition (UI 100–300lg/L), the hazard ratios (HRs) of all-cause mortality in the category with UI
‡300lg/L were 1.04 (95% confidence interval [CI 0.54–1.98]); however, in the categories with 50–99 UI and <50lg/L,
the HRs were 1.29 [CI 0.97–1.70] and 1.71 [1.18–2.48], respectively ( p for trend 0.004). Multivariate adjustment did not
significantly modify the results.
Conclusions: Our data indicate an excess mortality in individuals with moderate-severe ID adjusted for other
possible confounding factors.
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Iodine is a trace element that is essential for the synthesisof thyroid hormones. Iodine deficiency (ID) can lead to
goiter, thyroid dysfunction, cognitive impairment, and de-
layed physical development (1).
Despite progress in strategies for preventing and control-
ling ID, ID disorders continue to be a major public health
problem throughout the world. It is estimated that >2000
million people worldwide are still at risk of insufficient io-
dine intake, 459.7 million in Europe (2). In Spain, although
the evolution of iodine nutrition in recent years has been
favorable placing our country globally as with ‘‘adequate
iodine nutrition,’’ there is still evidence that a large propor-
tion of the population remains iodine deficient (3). Moreover,
there is a lack of policies concerning monitoring systems on
the population iodine status, or in the prevention of ID, such
as universal salt iodization, as recommended by the World
Health Organization (WHO) and United Nations Interna-
tional Children’s Emergency Fund (UNICEF) (4).
As most iodine ingested by the body is excreted in urine
(90%), urinary iodine (UI) reflects recent dietary iodine in-
take, therefore the assessment of iodine intake is mostly
based on urinary excretion. Studies have convincingly dem-
onstrated that a profile of iodine concentrations in morning
or other random urine specimens provides an adequate as-
sessment of a population’s iodine nutrition, when provided
by a sufficient number of individuals (1).
Assessing an association between ID and mortality beyond
its effects on thyroid function would stress the need to im-
plement preventive strategies focused on its eradication.
However, longitudinal data studying the impact of iodine
nutrition on mortality are scarce.
The aim of this study was to investigate if there is an
association between the state of iodine nutrition, measured as
UI in a random urine sample, and the risk of total and cause-




The Di@bet.es Study is a national, cross-sectional,
population-based survey conducted in 2009–2010 (5–7).
A cluster sampling design was used to select participants to
form a representative random sample of the Spanish popu-
lation. One hundred health centers or their equivalent from all
around the country were selected randomly, with a proba-
bility for selection proportional to their target population size
(Fig. 1), after which 100 individuals aged ‡18 years were
randomly selected from each health center. Of the eligible
adults, 55.8% were evaluated, and 9.9% were excluded
(because they were institutionalized, had severe disease, were
pregnant, or recently delivered), resulting in a final sample
of 5072 individuals.
We selected 4383 subjects for this study for whom UI
measurements were available. In addition, we excluded 13
subjects on treatment with amiodarone, usually prescribed
for cardiac arrhythmia, which contents a high amount of io-
dine in its composition. All these 13 subjects had UI con-
centrations >400 lg/L.
The research was carried out in accordance with the De-
claration of Helsinki (8) of the World Medical Association.
Written informed consent was obtained from all the partici-
pants. The study was approved by the Ethics and Clinical In-
vestigation Committee of the Hospital Regional Universitario
de Málaga (Malaga, Spain) in addition to other regional ethics
and clinical investigation committees all over Spain.
Variables and procedures
The participants were invited to attend a single examination
visit at their health center. Information was collected using an
interviewer administered structured questionnaire, followed
by a physical examination and blood and urine sampling.
Information on age, sex, educational level, smoking status,
and other sociodemographic variables was obtained using
FIG. 1. Map showing the
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a questionnaire. Food consumption was determined by a
40-item food frequency questionnaire. The questionnaire in-
cluded the assessment of dairy and iodinated salt consumption.
Adherence to a Mediterranean diet was estimated by a modi-
fied version of a validated 14-item Mediterranean diet score
(MedScore) (9). The level of daily physical activity was esti-
mated by the short form of the International Physical Activity
Questionnaire (10). Self-reported previous diagnoses of car-
diovascular disease and cancer were also recorded.
Weight and height were measured by standardized methods.
The body mass index (BMI) was calculated. A BMI ‡30 kg/m2
was considered as representing obesity (11). Blood pressure
was measured using a blood pressure monitor (Hem-703C;
Omron, Barcelona, Spain) after several minutes in a seated
position; the mean of two measurements taken after at least
two minutes apart was used for analysis. Hypertension was
considered if there was a previous clinical diagnosis of hy-
pertension, and/or systolic blood pressure was ‡140 mmHg
and/or diastolic blood pressure was ‡90 mmHg (12).
Participants with baseline capillary blood glucose levels
<7.8 mmol/L (measured by OneTouch system; Lifescan,
Johnson & Johnson, S.A.) and not receiving treatment for
diabetes mellitus (DM) underwent a standard oral glucose
tolerance test, obtaining fasting and two hours venous sam-
ples (8–10 hours fasting samples were obtained between 8:30
a.m. and 10:00 a.m.). Samples were immediately centrifuged,
and the serum was frozen until analysis.
Serum glucose, triglycerides, and cholesterol were mea-
sured enzymatically and high-density lipoprotein cholesterol
by a direct method. The diagnosis of DM was based on the
1999 WHO criteria (13). Hypercholesterolemia was defined
as total cholesterol concentration ‡240 mg/dL or treatment
with lipid lowering drugs (14).
Creatinine was analyzed with the modified Jaffe method
(Randox Laboratories Ltd., Antrim, United Kingdom), using an
A15 autoanalyzer (BioSystems, Barcelona, Spain) (15). Esti-
mated glomerular filtration rate (eGFR) was calculated according
to the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation (16). CKD was defined by CKD-EPI
equation–calculated eGFR <60 mL/min/1.73 m2 (16).
Thyrotropin (TSH), free triiodothyronine, and free thy-
roxine were measured by chemoluminescence in a modular
analytics E170 analyzer (Roche Diagnostics GmbH, Man-
nheim, Germany). Thyroid dysfunction was considered in
individuals on treatment with levothyroxine and/or thiona-
mides or with TSH levels >5 mIU/L or TSH <0.2 mIU/L (6).
UI measurements and classification
UI was analyzed using the modified method of Benotti and
Benotti (17). The intra- and interassay coefficients of varia-
tion of the UI assay were 2.01% and 4.53%, respectively. The
UI assay was subjected to external quality assessments for the
determination of iodine in urine by the Spanish Association
of Neonatal Screening and by the Ensuring the Quality of
Iodine Procedures program. All samples were analyzed in the
Research Laboratory of the Hospital Regional Universitario
de Málaga (Spain).
UI levels were classified according to current WHO,
UNICEF, and the Iodine Global Network (formerly Inter-
national Council for the Control of Iodine Deficiency Dis-
orders) recommendations (1): <50 lg/L moderate-severe
deficiency, 50–99 lg/L mild deficiency, 100–199 lg/L ade-
quate, 200–299 lg/L above requirements, and ‡300 lg/L
excessive. UI levels in this population (Di@bet.es) and its
conditioning factors have been previously reported (7).
Follow-up and assessment of fatal events
Mortality data were ascertained on December 31, 2016
by the National Spanish Statistics Institute (Instituto Na-
cional de Estadı́stica), from information on death certifi-
cates from the national death registry. The cause of death
was coded according to the International Classification of
Diseases, Tenth version ICD-10 of the WHO (18). Cardi-
ovascular death was defined with codes I00–I99 (‘‘diseases
of the circulatory system’’) or R96 (‘‘other sudden death,
cause unknown’’). Death due to cancer was defined with the
codes C00-D48 (‘‘neoplasms’’).
Statistical analysis
The study population was grouped into four categories
according to their UI concentrations (1). The sociodemo-
graphic characteristics of the study population as well as
other covariates of interest were determined in each category.
The number of events (deaths) was estimated for each group
calculating the mortality rates for each 1000 inhabitant-years
(95% confidence interval [CI]). We used the Kaplan–Meier
curves to describe all-cause mortality according to these ca-
tegories. Cox regression analysis was used to analyze the cor-
responding relative risks (RRs) of death, in crude models and in
multivariate models. The category with UI 100–300 lg/L was
used as a reference for the calculations of the RR.
As recommended, the selection of potential confounders
was based on the a priori existing knowledge, rather than
centered on statistical selection procedures (19–21). Potential
confounders included in the model were age, sex, education
level (no studies/basic/high school-college), area of residence
(south/center/east/north/northeast), hypertension (yes/no),
DM (yes/no), obesity (yes/no), CKD (yes/no), smoking (yes/
no), thyroid dysfunction (yes/no), prior cardiovascular disease
(yes/no), prior cancer (yes/no), hypercholesterolemia (yes/no),
medscore, physical activity (low/medium/high), dairy con-
sumption (<1 per day, 1 per day, ‡2 per day), and iodinated salt
consumption. To assure a minimum ratio of events per inde-
pendent variable of 10 (22), this multivariate regression model
requires a minimum of 180 events available for analyses.
Sensitivity analyses were reconducted under different as-
sumptions: (i) excluding participants with thyroid dysfunc-
tion and (ii) excluding participants with cardiovascular
disease or cancer.
All the statistical analyses were performed with IBM SPSS
statistics 23.0 and Epibasic 1.0 (University of Aarhus, Nordre
Ringgade, Denmark). Reported p-values were based on two-
sided tests with statistical significance set at 0.05.
Results
Clinical characteristics of the study sample according
to UI categories
The study sample comprised of 4370 individuals with a
mean age of 50.4 years (age range 18–93 years) and 57.4%
were female. Mean and median UI concentrations in the
population at baseline were 134.7 – 83 lg/L and 117.1 lg/L,
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respectively. Figure 2 shows the distribution of UI concen-
trations in the study sample. The distribution is concordant
with an iodine-sufficient population with no evidence of
significant overiodization. However, 29.7% of the population
had mild ID (UI 50–99 lg/L) and 9.7% had ID that was
moderate-severe (UI <50 lg/L).
Table 1 shows the clinical characteristics and the distribution
of the covariates in the sample according to UI concentrations.
There were no significant differences in the age and sex be-
tween groups. There were small differences in the education
level, with a higher proportion of individuals without studies in
both the categories with very low (<50lg/L) and excessive UI
(‡300 lg/L). There was also an imbalance in the distribution
of the area of residence across the categories. The prevalence
of cardiovascular risk factors and CKD was similar between
groups. Also, there were no significant differences regarding
adherence to med diet, physical activity, or in the proportion of
individuals reporting a previous history of cardiovascular dis-
ease or cancer. There was however a clearly higher proportion
of individuals with thyroid dysfunction in the excessive UI
(‡300 lg/L) category than in the rest of the categories. As ex-
pected, there was a strong association between the UI levels and
the consumption of iodine salt and dairy products.
UI categories and mortality
Overall, a total of 254 deaths in 31.901 person-years of
follow-up were recorded. The causes of death were cardio-
vascular, 71 (28%); cancer, 85 (33.5%); and other causes, 98
(38.5%). The mean duration of follow-up was 7.3 years.
Table 2 shows the mortality rates and hazard ratios (HRs)
for total mortality, and cardiovascular and cancer mortality
in the participants grouped in categories according to their
UI concentrations. In unadjusted models, participants with
moderate-severe ID (<50 lg/L) had a 70% relatively high
hazard of all-cause mortality compared with those with ad-
equate iodine nutrition (100–300 lg/L). There was also a
nonsignificant intermediate increase in the hazard (29%) in
the category with mild ID (50–99 lg/L) and a highly signif-
icant dose–response relation across the categories with
normal (100–300 lg/L), mild (50–99 lg/L), and moderate-
severe (<50 lg/L) ID ( p for trend 0.004). There was no sig-
nificant increase in the mortality hazards in the category with
excessive UI (‡300 lg/L). Multivariate adjustment of the
analyses did not induce any modification in the results.
Figure 3 includes the results of sensitivity analyses con-
ducted repeating the cox regression models for total mortality
in different scenarios (all population, excluding prevalent thy-
roid dysfunction and excluding prevalent cardiovascular dis-
ease or cancer). Apart from some minor changes, the direction
of the results was similar, and in all scenarios, a mortality
excess in the moderate-severe ID category could be observed.
Figure 4 graphically shows the Kaplan–Meier curves for
total mortality incidence according to UI groups, showing an
increase in the mortality curve in the category with UI
<50 lg/L during follow-up, which was already apparent after
four years of follow-up.
Specific analysis by causes of mortality was limited due
to the low number of estimates available. Acknowledging this
limitation, the analysis suggested a marked increase in car-
diovascular mortality, associated with ID (Table 2). Com-
pared with the reference, cardiovascular mortality crude HRs
were increased 2.1-fold in the category with mild ID (50–
99 lg/L), whereas moderate-severe ID (<50 lg/L) was asso-
ciated with a 2.4-fold increase. Again, there was a highly
significant dose–response relation in the hazards across these
categories ( p = 0.002). At higher UI (>300 lg/L), there was
also a 42% increase in the mortality risk, although the results
were not significant. After multivariate adjustment, only
moderate-severe deficiency (<50 lg/L) was significantly as-
sociated with an increase in the mortality risk (RR 2.38 vs.
reference), although a significant trend remained.
Unlike what was observed for cardiovascular mortality, no
significant associations between UI and cancer mortality
were observed, neither in the crude nor in the multivariate
models (Table 2).
FIG. 2. Distribution of the UI
concentrations in the study sample
(n = 4370). UI, urinary iodine.
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Discussion
Our results, evaluating a large representative sample of the
Spanish adult population with adequate iodine nutrition
monitored during an average follow-up of 7.3 years, showed
an association between moderate-severe ID and mortality
that remained after the adjustment for multiple potential
confounders. To the best of our knowledge, this association
had not been previously described, and, if confirmed, could
have important public health implications.
Despite our results being limited due to the low number of
estimates available, the specific analyses by causes of mortality
suggest that the association between ID and mortality was
mainly driven by cardiovascular causes. This fact, along with
the apparent independence of the association with the presence
of thyroid dysfunction at baseline, makes us hypothesize about
possible extrathyroid mechanisms with impact on the cardio-
vascular system as possible mechanisms of this association.
In this sense, several mechanisms could be involved:
(i) Iodine has well-known antioxidant and anti-
inflammatory effects (23). Micromolar amounts of
iodine decrease damage by free oxygen radicals and
increase the total antioxidant status in human serum
(24). It is also well established that povidone–iodine
exerts an anti-inflammatory action by neutralizing
radical oxygen species (25). Previous experimental
studies conducted by our group (26) demonstrated that
a daily dose of 100, 200, or 300 mg of iodide in the
form of potassium iodide for six months did not modify
thyroid function, but had some anti-inflammatory ef-
fects; on day 60 of the treatment, UI concentration
correlated with C-reactive protein (r 0.461, p = 0.018),
and with the changes produced in a1-antitrypsin (r
0.475, p = 0.014) and ceruloplasmin (r 0.599, p = 0.001).
Another previous study by our group also demonstrated
that iodine is involved in the regulation of oxidative
stress and adiponectin levels in human breast milk (27).
(ii) Hemodynamic effects: Iodinated soluble radiogra-
phic contrast media induce vasodilatation, which is
associated with increased blood flow, decreases in
vascular peripheral resistance, and variations in sys-
temic and peripheral arterial blood pressure (28). It is
not clear if iodine itself can exert some of these ef-
fects. It is noteworthy that iodine infusions have been
shown to reduce heart damage by as much as 75% in
a mouse model of acute myocardial infarction (29).
Table 1. Baseline Characteristics of the Study Sample According to Urinary Iodine Concentrations
Urinary iodine (lg/L)
p Value
for difference<50 50–100 100–300 >300
Number 426 1299 2454 191
Age (years) 50.3 – 16.4 49.9 – 16.5 50.5 – 16.9 52.6 – 16.5 0.217
Sex (female) (%) 57.0 57.0 57.4 60.7 0.804
Educational level (%)
No studies 16.3 12.2 11.4 18.3
Basic 47.2 49.4 47.9 50.3 0.004
High school-college 36.6 38.4 40.5 31.4
Area of residence (%)
North 22.1 10.5 8.2 12.6
Center 25.1 26.1 28.0 21.5 <0.001
Northeast 16.4 17.2 16.9 18.3
East 11.7 11.1 14.4 17.8
South 24.6 35.2 32.4 29.8
Smoking (%) 25.9 26.2 26.0 25.1 0.992
Hypertension (‡140/90) (%) 47.3 45.6 43.8 47.6 0.366
Diabetes (WHO 1999) (%) 15.5 14.1 12.4 13.1 0.209
Obesity (%) 29.2 30.2 31.5 27.7 0.553
Hypercholesterolemia (‡240 mg/dL) (%) 21.2 25.4 26.2 25.3 0.207
CKD (eGFR <60 mL/min) (%) 5.9 7.6 6.7 7.0 0.642
Thyroid dysfunction (%) 8.1 7.1 11.9 24.2 <0.001
Mediterranean diet score 7.8 – 1.8 7.7 – 1.8 7.8 – 1.7 7.9 – 1.8 0.375
Physical activity (SF-IPAQ) (%)
Low 39.2 44.3 42.4 41.4
Medium 38.9 34.6 32.8 37.2
High 21.9 21.1 24.8 21.5 0.053
Previous cardiovascular disease (%) 5.2 6.6 7.4 7.9 0.358
Previous history of cancer (%) 1.2 0.8 1.3 1.6 0.652
Iodized salt intake (%) 32.8 33.4 42.3 51.3 <0.001
Dairy consumption (%)
<1 Per day 17.0 11.2 8.7 8.4
1 Per day 24.3 22.3 21.0 20.9
‡2 Per day 58.7 66.5 70.3 70.7 <0.001
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; SF-IPAQ, short form of the International Physical Activity
Questionnaire; WHO, World Health Organization.
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(iii) Antiatherosclerotic effects: ID has also been associated
with dyslipidemia (30), and iodine treatment has been
shown to reduce serum lipid levels (31,32). Animal
studies, performed as early as the 1930s, clearly dem-
onstrated that iodine compounds can prevent the de-
velopment of atherosclerosis in rabbits (33,34). Also at
the epidemiological level, low iodine levels have been
associated with an increased prevalence of coronary
artery disease in adults without thyroid dysfunction (35).
Although some of these mechanisms could theoretically
explain an effect of ID in the cardiovascular system inde-
pendently of thyroid function, it is also noteworthy that
although we controlled our analyses by prevalent thyroid
dysfunction at baseline, we cannot disregard an increased
incidence of thyroid dysfunction during follow-up as a me-
diator of the association between ID and mortality. Moreover,
even in subjects with normal thyroid hormone levels, ID
could be associated with insufficient cardiac tissue levels of
thyroid hormones, as has been addressed in animal models
in studies by Escobar del Rey et al. (36).
Finally, different studies have suggested an association
between ID and breast and prostate cancer (37–39). This
antineoplastic effect has been hypothesized as being caused
by different mechanisms and pathways. The oxidized iodine
dissipates the mitochondrial membrane potential, thereby
triggering mitochondrion-mediated apoptosis. Another mech-
anism would be iodolipid formation and the activation of
peroxisome proliferator-activated receptors type gamma,
which triggers the BAX-caspase apoptotic pathway (40).
Although in our study we did not observe an increase in
cancer mortality, the low statistical power of the analysis
does not allow us to draw any definitive conclusion.
It is noteworthy that the descriptive design of our study
does not allow us to confirm or reject any of these hypotheses
to explain our results that we present as merely speculative.
To the best of our knowledge, there is only one previous
epidemiological study assessing the association between io-
dine status and mortality with a prospective design and in-
terestingly, the results are not concordant with our study (41).
Inoue et al. (41) estimated mortality risks according to UI
concentrations utilizing a nationally representative sample
of 12,264 adults aged 20–80 years enrolled in the National
Health and Nutrition Examination Survey III over a median
follow-up of 19.2 years. According to their results,
FIG. 3. All-cause mortality according to UI categories in
different scenarios. Data show relative risk for total mor-
tality and 95% confidence interval in multivariate-adjusted
cox models.
Table 2. Cox Proportional Hazard Ratios (95% Confidence Intervals) for All-Cause, Cardiovascular,
and Cancer Mortality According to Urinary Iodine Categories (World Health Organization–United
Nations International Children’s Emergency Fund)*
Urinary iodine (lg/L)
p
for trenda<50 50–99 100–299 ‡300
Patients (n) 426 1299 2454 191
All-cause mortality
Deaths (n) 36 84 124 10
Mortality/1000 person-years [CI] 11.8 [8.2–16.3] 8.9 [7.1–11.0] 6.9 [5.8–8.2] 7.2 [3.4–13.2]
RR crude [CI] 1.71 [1.18–2.48] 1.29 [0.97–1.7] 1 (reference) 1.04 [0.54–1.98] 0.004
RR multivariate [CI] 1.71 [1.12–2.61] 1.28 [0.94–1.75] 1 (reference) 1.07 [0.54–2.15] 0.010
Cardiovascular mortality
Deaths (n) 11 30 27 3
Mortality/1000 person-years [CI] 3.6 [1.8–6.4] 3.2 [2.1–4.5] 1.5 [1.0–2.2] 2.2 [0.4–6.3]
RR crude [CI] 2.40 [1.19–4.85] 2.10 [1.25–3.54] 1 (reference) 1.43 [0.43–4.72] 0.002
RR multivariate [CI] 2.38 [1.05–5.40] 1.82 [1.00–3.32] 1 (reference) 1.58 [0.46–5.42] 0.011
Cancer mortality
Deaths (n) 11 26 44 4
Mortality/1000 person-years [CI] 3.6 [1.8–6.4] 2.8 [1.8–4.0] 2.5 [1.8–3.3] 2.9 [0.8–7.4]
RR crude [CI] 1.47 [0.76–2.85] 1.12 [0.69–1.82] 1 (reference) 1.17 [0.42–3.25] 0.314
RR multivariate [CI] 1.33 [0.62–2.82] 1.07 [0.63–1.83] 1 (reference) 1.31 [0.46–3.74] 0.443
*Reference (1).
Multivariate: age, sex, education level (no studies/basic/high school-college), hypertension (yes/no), diabetes (yes/no), obesity (yes/no),
ckd (yes/no), smoking (yes/no), thyroid dysfunction (yes/no), prior cardiovascular disease (yes/no), prior cancer (yes/no), hypercholester-
olemia (yes/no), area of residence (south/center/east/north/northeast), Med_score, SF-IPAQ (low/medium/high), dairy consumption (<1 per
day, 1 per day, ‡2 per day), iodinated salt consumption (yes/no)
In bold p < 0.05 versus UI 100–299 lg/L (reference).
ap for trend across categories with UI 100–299 lg/L (reference), 50–99 lg/L, and <50 lg/L.
RR, relative risk; CI, 95% confidence interval; UI, urinary iodine.
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participants with excess iodine exposure (UI >400 lg/L)
were at a higher risk of all-cause mortality compared with
those with adequate iodine nutrition (HR, 1.19; [CI 1.04–
1.37]), whereas low UI concentration was not associated with
an increased mortality.
Differences in the background population, including dif-
ferent iodine nutrition status in the United States compared
with the Spanish population, differences in diet, could partially
account for these differences. Also, it is known that the sus-
ceptibility of individuals to excessive or insufficient iodine
intake is dependent on the geographical area of residence, and
this information was not available in the Inoue et al. (41) study,
hence analyses could not be suitably adjusted accordingly. It
also seems to us that a long follow-up of 19.2 years makes
more likely that a shift to an increased intake of iodine in the
ID group during time could have occurred, potentially biasing
the mortality estimates toward null. There are also other dif-
ferences in the statistical approach between the studies.
Although some of these factors could be considered partially
explanatory, we do not have a definitive explanation to account
for the differences in the results of these two studies, and clearly
more data from other prospective studies are necessary.
It is interesting to note that we were not able to study the
group with very high UI (‡400 lg/L), associated with an
increased mortality in the Inoue et al. (41) study, due to the
very low number of subjects in that group. so Therefore, we
cannot discard or confirm an increased mortality in this
segment of the population.
Our study has several limitations. First, iodine status was
estimated only from a single spot urine measurement. While
UI in spot samples is a well-validated biomarker of iodine
status for population assessments (1), individual assessment is
challenging, and probably requires repeated samples to ac-
count for intraindividual day-to-day variability (42–44). Fu-
ture studies should try to overcome this limitation by repeating
UI assessments in at least part of the study population.
Second, we excluded from analyses any participants under
amiodarone treatment, but could not exclude the possibility
that participants had received iodinated contrast and both
patients affected by cancer or cardiovascular disease may
have had iodinated contrast computed tomography scans or
angiography. Prevalent diagnosis of cancer or cardiovascular
disease was introduced in the analysis as a covariate. Also,
sensitivity analyses excluding participants with these diag-
noses showed similar results.
Third, unlike the Inoue et al. (41) study, we were not able
to adjust the results by sodium intake, but as iodine intake is
strongly linked to sodium intake (in the form of iodized salt)
(45) and sodium excess is associated with a higher risk of
hypertension and cardiovascular disease (46), not including
this variable in the analyses could, if anything, most likely
generate a bias toward null.
Finally, the main limitation lies in the relatively small
sample size with limited number of events available for an-
alyses and in the observational cohort nature of the design,
hence we cannot establish causal associations or exclude
residual confounding factors.
In conclusion, our study shows an association between ID
and mortality in Spanish adults, which seems to be driven
mostly by cardiovascular causes. The discrepancy with pre-
vious studies, and the limited sample size and number of
events, stress the need for further studies to clarify the rela-
tion between iodine status and mortality and cardiovascular
disease in the general population.
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